
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - In an overview of tests needed to diagnose patients with cutaneous manifestations of collagen vascular disease,